Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Substudy Supports Reduced Risk of Metastasis and Death
· newswise.com · popularity 16/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at newswise.com →
Summary
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide -- a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) -- plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care. The substudy, co-led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, was presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain and published today in European Urology.
Found in: Newswise. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 18.